Review Article

Reference pricing systems in Europe: characteristics and consequences

Published in: Volume 1 / Year 2012 / Issue 3-4
Author(s): , ,
Page: 127-131

Author byline as per print journal: Pieter Dylst, PharmD; Professor Steven Simoens, MSc, PhD; Professor Arnold G Vulto, PharmD, PhD Introduction: A reference pricing system is a system that establishes a common reimbursement level… Read More »

Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach

Published in: Volume 1 / Year 2012 / Issue 2
Author(s): ,
Page: 69-83

Author byline as per print journal: Brian Godman1,2,3, BSc, PhD; Mohammed Abuelkhair4, PharmD; Agnes Vitry5, PharmD, PhD; Shajahan Abdu4, MD; Marion Bennie6,7, MSc; Iain Bishop7, BSc; Sahar Fahmy4, PhD; Kristina Garuoliene8,… Read More »

What lessons can be learned from the launch of generic clopidogrel?

Published in: Volume 1 / Year 2012 / Issue 2
Author(s): ,
Page: 58-68

Author byline as per print journal: Christoph Baumgärtel1, MD; Brian Godman2,3,4, BSc, PhD; Rickard E Malmstrom5, MD, PhD; Morten Andersen6, MD, PhD; Mohammed Abuelkhair7, PharmD; Shajahan Abdu7, MD; Marion Bennie8,9, MSc;… Read More »

A review of patient perspectives on generics substitution: what are the challenges for optimal drug use

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 28-32

Author byline as per print journal: Helle Håkonsen, MScPharm, PhD; Else-Lydia Toverud, MScPharm, PhD Introduction: With a few exceptions, generic drug use has been promoted in western countries by allowing pharmacists to… Read More »

European payer initiatives to reduce prescribing costs through use of generics

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 22-7

Author byline as per print journal:  Brian Godman1,2,3, BSc, PhD; Bjorn Wettermark1,4, MSc, PhD; Iain Bishop5, BSc; Thomas Burkhardt6, MSc; Jurij Fürst7, PhD; Kristina Garuoliene8, MD; Ott Laius9, MScPharm; Jaana E Martikainen10,… Read More »

A patient-centred paradigm for the biosimilars market

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 17-21

Abstract:  The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for… Read More »

Biologicals and biosimilars: a review of the science and its implications

Published in: Volume 1 / Year 2012 / Issue 1
Author(s):
Page: 13-6

Abstract:  Biopharmaceuticals are medicines whose active drug substance is made by living cells. Copies of these drugs, called biosimilars, are not identical to their reference drug and therefore specific regulatory… Read More »

A review of generic medicine pricing in Europe

Published in: Volume 1 / Year 2012 / Issue 1
Author(s):
Page: 08-12

Introduction: Switching from originator products to generic equivalents is a key method used by governments to reduce costs and keep their healthcare systems sustainable. The aim of this article is to review… Read More »

Are there biosimilar orphan drugs for Gaucher disease? An overview in Mexico

Author(s): , , , , , , , ,

Abstract: Enzyme replacement therapy (ERT) is the first-line treatment for Gaucher disease (GD). The ERT Cerezyme™ (imiglucerase) was approved by the US Food and Drug Administration (FDA) in 1994; however,… Read More »

Global landscape of biosimilars: literature review

Author(s): , ,

Abstract: Biopharmaceuticals have been defined as “pharmaceuticals inherently biological in nature and manufactured using biotechnology” [1]. The first part of this definition distinguishes biopharmaceuticals from chemically synthesized ‘small molecule drugs’,… Read More »

Page 4 of 4 « Previous1 2 3 4
Go Back Print